The MS Academy is hosting a series of educational webinars over the coming weeks to address some of the challenges with managing specific neurological conditions, or elements of neurological conditions, during the COVID-19 pandemic.
Please note that all session and slide content are the views of the Speakers, not the MS Academy. The content of the recording is the speaker’s personal opinion at the time of recording. Due to the everchanging situation, advice given at the time of recording is subject to change.
These meetings have been sponsored by Roche Products Limited. Roche Products Limited has had no control over the educational content of this activity.
10 July | Dr David Paling, Prof Gavin Giovannoni & Dr Rachel Farrell
1 July 2020 | Ruth Stross, Dr Agne Straukiene, Margie Leong, Sherridan Daly, Kim Knight, Camille Whitehead & Jacqueline Rose
26 June 2020 | Prof Gavin Giovannoni, Dr Ruth Dobson, Dr Stefano Pluchino and Prof Anna Williams
19 June 2020 | Prof Gavin Giovannoni, Alyson McGregor, Bernadette Porter, Amy Harbour & George Pepper
8 June 2020 | Joela Mathews & Rachel Dorsey-Campbell
Formalising remote management of MS – Making sure when we get back to normal we continue to use what we have learnt
4 June 2020 | Prof Jeremy Hobart, Dr David Paling, Dr Wallace Brownlee & Daisy Cam
27 May 2020 | Dr Ruth Dobson & Prof Gavin Giovannoni
20 May 2020 | Prof David Baker & Prof Gavin Giovannoni
13 May 2020 | Prof Richard Nicholas, Prof Marco Salvetti & Prof Gavin Giovannoni
6 May 2020 | Prof Gavin Giovannoni
29 April 2020 | Prof Gavin Giovannoni, George Pepper, Megan Roberts & Jody Barber
22 April 2020 | Prof Gavin Giovannoni, George Pepper, Joela Mathews, Phillip Anderson & Megan Roberts
17 April 2020 | Prof Jeremy Hobart & Dr David Paling
14 April 2020 | Dr Niall MacDougall, Dr Brendan McLean, Rachel Morrison & Joela Mathews
9 April 2020 | Jo Johnson & Ruth Stross
6 April 2020 | Jo Johnson, Prof Jeremy Hobart, George Pepper & Ruth Stross
3 April 2020 | Prof Jeremy Hobart, Rachel Dorsey-Campbell & Sarah White
Debate: Should ocrelizumab & cladribine be treated in the same way as alemtuzumab in terms of COVID-19 risk?
31 March 2020 | Prof Klaus Schmierer & Prof David Baker
27 March 2020 | Prof Gavin Giovannoni, David Martin, George Pepper, Phillip Anderson & Rachel Dorsey-Campbell
25 March 2020 | Prof Basil Sharrack & Prof John Snowden
The above meetings have been sponsored by Roche Products Limited. Roche Products Limited has had no control over the educational content of this activity.
18 March 2020 | Dr Sharmilee Gnanapavan
18 March 2020 | Prof Gavin Giovannoni